FWM
ALXN

Frontier Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Frontier Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,289
Closed -$274K – 418
2017
Q4 		$274K Buy
+2,289
New +$279K 0.04% 282
2016
Q1 		– Sell
-1,088
Closed -$208K – 373
2015
Q4 		$208K Buy
+1,088
New +$190K 0.03% 312

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Frontier Wealth Management's ALXN Position: Q1 2018 in Review

Frontier Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 2,289 shares — an estimated $274K sold.

Frontier Wealth Management first reported a position in ALXN in Q4 2015 and held it in 2 quarters. The position peaked at $274K in Q4 2017. 596 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • Frontier Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Frontier Wealth Management sold 2,289 Alexion Pharmaceuticals shares in Q1 2018, an estimated $274K.
  • Frontier Wealth Management first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Frontier Wealth Management's Alexion Pharmaceuticals position peaked at $274K in Q4 2017.
  • 596 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Frontier Wealth Management's 13F filing for Q1 2018, filed 15 May 2018.